This web site is intended to provide systemic anaplastic large cell lymphoma (ALCL) patients and their families with information on clinical trials sponsored by Seattle Genetics.

For additional information on these clinical trials, please go to clinicaltrials.gov or click on the links below.

A phase 2 open label trial of SGN-35 for patients who have previously participated in an SGN-35 study

A phase I study of brentuximab vedotin administered sequentially or concurrently with multi-agent chemotherapy as front-line treatment in patients with systemic anaplastic large cell lymphoma

Comments and feedback
If you have questions or comments, please send an email to clinicaltrials@seagen.com. ALCL.com will not reply to requests related to management of individual patients and should not be used as an alternative to consultation with the patient's health care professionals.

The contents of ALCL.com, such as text, graphics, images and other information on this site ("Content") are for informational purposes only.  The Content is not intended to be a substitute for professional medical advice, diagnosis or treatment.  Always seek the advice of your physician or other qualified health provider with any questions you may have regarding your specific medical condition.  Never disregard professional medical advice or delay in seeking it because of something you have read on the ALCL.com site.